CARESTART
COVID-19
IgM/IgC
Rapid Diagnostic Test for the Detection of SARS-CoV-2 IgM/IgG Ab
ACCESS BIO’S CARESTART™ COVID-19 lgM/lgG
RAPID COVID-19 TESTING TOOL
NOW FDA EMERGENCY USE AUTHORIZED
SARS-CoV-2, A highly contagious novel virus, had severely impacted the U.S. and global healthcare system and economy. A rapid in vitro testing is a key component to identify and mitigate the spread. The CareStart™ Covid 19 IgM/IgG Rapid Diagnostic Test for the Detection of SARS-CoV-2 IgM/IgG Ab provides a fast and easy diagnostic tool for COVID-19 in the limited testing environment.
- Fast and easy to use in a qualified CLIA setting
- Detect and differentiate IgM/IgG antibody specific to SARS-CoV-2.
- Requires small sample volume (10 uL of venous whole blood, serum, or plasma)
- Results available in 10 minutes.
- No equipment or training required.
- Identify and monitor individual’s previous infection history and immune response to COVID-19.
- Clinical performance (NIH/NCI) of 100% sensitivity and 97.5% specificity.
- CE certified.
TEST
PRINCIPLES
The CareStart™ Covid 19 IgM/IgG Rapid Diagnostic Test for the Detection of SARS-CoV-2 IgM/IgG Ab is a lateral flow immunochromatographic assay which can differentiate SARS-CoV-2 Immunoglobin IgM and IgG antibodies in human blood specimens in a single test within 10 minutes.
procedure
PROCEDURE
STEP 1
Add 10µl of the sample (whole blood, serum, or plasma).
STEP 2
Add 1 drop of Assay
Buffer
STEP 3
Read the test results after 10 minutes.
RESULTS INTERPRETATION
RESULTS
INTERPRETATION
Covid-19 Positive
Covid-19 Negative
Invalid
ORDER INFORMATION
ORDER
INFORMATION
CAT. NO. | RCHM-02072 |
PACKAGE UNIT | 20 TESTS / KIT |
KIT COMPONENT | 20 TEST DEVICES |
PRODUCT DOCUMENTATION
